VTRS Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 104 min ago

@ $11.76

Ausgestellt: 29 Apr 2024 @ 21:47

Rendite: 0.21%

Vorheriges Signal: Apr 29 - 19:11

Vorheriges Signal: Kaufen

Rendite: 0.21 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets...

Stats
Tagesvolumen	3.97M
Durchschnittsvolumen	8.81M
Marktkapitalisierung	13.99B
EPS	$0 ( 2024-02-28 )
Nächstes Ertragsdatum	( $0 ) 2024-05-06
Last Dividend	$0.120 ( 2023-11-22 )
Next Dividend	$0 ( N/A )
P/E	235.60
ATR14	$0.301 (2.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Le Goff Corinne	Buy	110 162	Restricted Stock Units
2024-04-18	Le Goff Corinne	Buy	78 688	Restricted Stock Units
2024-04-15	Le Goff Corinne	Buy	0
2024-04-02	Malik Rajiv	Buy	18 845	Restricted Stock Units
2024-03-13	Mauro Anthony	Sell	250 000	Common Stock

INSIDER POWER
9.39
Last 99 transactions
Buy: 1 339 847 \| Sell: 1 117 278

Volumen Korrelation

Lang: 0.57 (weak)

Kurz: 0.24 (neutral)

Signal:(84) Neutral

Viatris Inc. Korrelation

10 Am meisten positiv korreliert
MMAC	0.897
NETE	0.888
SRAC	0.833
AMRB	0.83
RAVN	0.829
BRKH	0.824
DOOO	0.824
EUSG	0.819
BOCH	0.817
TKNO	0.816

10 Am meisten negativ korreliert
SVOK	-0.94
PAIC	-0.907
SVAC	-0.9
RMRM	-0.883
FEYE	-0.846
TLGT	-0.841
SPRT	-0.83
FTOCU	-0.823
FTOC	-0.815
OPCH	-0.808

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Viatris Inc. Korrelation - Währung/Rohstoff

0.52
( weak )

0.77
( moderate )

0.00
( neutral )

-0.43
( neutral )

Viatris Inc. Finanzdaten

Annual	2023
Umsatz:	$15.38B
Bruttogewinn:	$6.57B (42.70 %)
EPS:	$0.0456

FY	2023
Umsatz:	$15.38B
Bruttogewinn:	$6.57B (42.70 %)
EPS:	$0.0456

FY	2022
Umsatz:	$16.26B
Bruttogewinn:	$6.50B (39.95 %)
EPS:	$1.710

FY	2021
Umsatz:	$17.89B
Bruttogewinn:	$5.58B (31.17 %)
EPS:	$-2.11

Financial Reports:

No articles found.

Viatris Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.120 (N/A)	$0.120 (N/A)	$0.120 (N/A)	$0.120 (N/A)	$0.240 (N/A)	$0.120 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Viatris Inc. Dividend Information - Dividend King

Dividend Sustainability Score: 6.81 - average (93.69%) | Divividend Growth Potential Score: 4.62 - Stable (7.56%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00741	1986-12-24
Last Dividend	$0.120	2023-11-22
Next Dividend	$0	N/A
Payout Date	2023-12-15
Next Payout Date	N/A
# dividends	88	--
Total Paid Out	$2.99	--
Avg. Dividend % Per Year	2.32%	--
Score	5.02	--
Div. Sustainability Score	6.81
Div.Growth Potential Score	4.62
Div. Directional Score	5.72	--

Next Divdend (Est)
(2024-06-03)

$0.123 Estimate 35.64 %

Dividend Stability

0.71 Good

Dividend Score

5.02

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1986	$0.00741	0.28%
1987	$0.0148	0.88%
1988	$0.0111	0.86%
1989	$0.0148	1.13%
1990	$0.0222	0.63%
1991	$0.0296	1.01%
1992	$0.0326	0.53%
1993	$0.0416	0.46%
1994	$0.0564	0.78%
1995	$0.0652	0.85%
1996	$0.0712	0.70%
1997	$0.0712	0.97%
1998	$0.0712	0.80%
1999	$0.0712	0.53%
2000	$0.0712	0.66%
2001	$0.0712	0.65%
2002	$0.0756	0.47%
2003	$0.0966	0.61%
2004	$0.120	0.48%
2005	$0.210	1.20%
2006	$0.240	1.20%
2007	$0.120	0.60%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0.330	1.78%
2022	$0.480	3.38%
2023	$0.600	5.27%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00355	1.500	9.93	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00115	1.200	9.96	10.00	[0 - 0.3]
returnOnEquityTTM	0.00263	1.500	-1.082	-1.623	[0.1 - 1]
payoutRatioTTM	10.52	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.572	0.800	7.14	5.71	[1 - 3]
quickRatioTTM	0.658	0.800	-0.833	-0.666	[0.8 - 2.5]
cashRatioTTM	0.128	1.500	-0.401	-0.602	[0.2 - 2]
debtRatioTTM	0.382	-1.500	3.63	-5.45	[0 - 0.6]
interestCoverageTTM	1.886	1.000	-0.413	-0.413	[3 - 30]
operatingCashFlowPerShareTTM	2.33	2.00	9.22	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.937	2.00	9.03	10.00	[0 - 20]
debtEquityRatioTTM	0.890	-1.500	6.44	-9.66	[0 - 2.5]
grossProfitMarginTTM	0.419	1.000	6.36	6.36	[0.2 - 0.8]
operatingProfitMarginTTM	0.0708	1.000	-0.585	-0.585	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.154	1.000	-0.257	-0.257	[0.2 - 2]
assetTurnoverTTM	0.323	0.800	-1.178	-0.943	[0.5 - 2]
Total Score				6.81

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	253.84	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.00263	2.50	-0.695	-1.623	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.937	2.00	9.35	10.00	[0 - 30]
dividendYielPercentageTTM	4.15	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.33	2.00	9.22	10.00	[0 - 30]
payoutRatioTTM	10.52	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	-1.592	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.182	1.000	7.96	0	[0.1 - 0.5]
Total Score				4.62

Viatris Inc.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.